Vaccine For Influenza Articles & Analysis
23 articles found
Researchers are working on mRNA vaccines for influenza, Zika virus, and even HIV. In 2024, we can expect to see clinical trials that leverage this technology, aiming for a more efficient and rapid response to viral outbreaks. Additionally, the use of viral vectors and protein subunit vaccines is being explored to increase vaccine ...
Due to the flexibility of this class of vaccines in developing vaccines against highly variable pathogens, many vaccine candidates are currently in development, including COVID-19 (95 candidates), influenza (24), and HIV (21). ...
Because outside of supporting his region’s vaccination needs at CSL Seqirus, leading influenza vaccines provider, you’ll find him coaching the Puerto Rico Women’s National lacrosse team. ...
Infectious diseases like influenza can be threats to public health and our economy. At the OPTIONS XI for the Control of Influenza conference, leading influenza vaccines provider CSL Seqirus, joined academic, government, research and industry stakeholders to discuss and learn more about influenza and its impact. ...
“We’re also battling the trolls and conspiracy theorists that push misinformation and undermine the outbreak response.” Vaccine-preventable diseases like COVID-19 and influenza continue to pose a significant public health threat. Vaccination is critical to protecting communities and reducing their spread. Although, with an ...
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s ...
School is back in session, here’s what you need to know to help keep your family protected from flu. Influenza can be a real burden. It can spread rapidly between children and their families to have a significant impact on quality of life and disruption of usual activities: resulting in missed school days and for caregivers, missed work and illness themselves. ...
Experts discuss global implications of the surge. “Influenza is definitely back in the Southern Hemisphere,” said Professor Ian Barr, Deputy Director of The World Health Organization Collaborating Centre for Reference and Research on Influenza, during a recent BioMelbourne Network event. ...
Longlong Si's research group from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published a research titled "Generation of a live attenuated influenza A vaccine by proteolysis targeting" in Nature Biotechnology. Using influenza virus as a model virus, the team established the ...
Influenza vaccine manufacturing is an intricate and complex process that culminates in the summer months, when U.S. flu vaccine manufacturers receive regulatory approval from the FDA for the season’s vaccines. ...
Tab Lassiter – an employee of global vaccines leader CSL Seqirus – is about to receive a second transplant in an ongoing battle with a heart condition. ...
But as daily life slowly returns to normal – and in the absence of an effective call to action on getting an annual influenza vaccine – we must not let our guard down amidst the ever-present threat of influenza. ...
Making influenza vaccines that can help protect against viruses that threaten human health isn’t a simple process. It requires the cooperation between influenza vaccine manufacturers like Seqirus, and the World Health Organization’s (WHO) 158 laboratories in 127 countries and 7 collaborating centers that comprise its ...
The study will evaluate the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication, intranasal M2SR influenza (flu) vaccine, and high dose inactivated vaccine (IIV). There is a demonstrated unmet need for improved flu vaccine options, as current injectable ...
[i] To make sure influenza vaccinations are effective, they must be stored at the proper temperature. ...
This is believed to be the first demonstration of vaccine-induced protection against a highly drifted H3N2 influenza virus in a human challenge study. “Current vaccines are strain-specific and in recent years they have had low efficacy against H3N2 influenza, especially when the vaccine is mismatched to ...
Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu – Safety and immunogenicity study expected to begin in Q2 2022 – MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage ...
Previous studies have also demonstrated that, unlike currently licensed influenza vaccines administered by intramuscular injection, intranasal M2SR stimulates mucosal and cellular immunity as well as serum humoral immunity. ...
Last week, the product manager of Creative Enzymes announced the launch of neuraminidase, which is expected to further develop a new universal influenza vaccine. Neuraminidase is a drug target to prevent the spread of influenza infection. ...
“The concept of self-medication isn’t going away, even after the pandemic ends: we’ve learned to adapt to telemedicine, and the self-administration of therapeutics and vaccines isn’t far behind,” Mr. Damon contends. Micron has completed a Phase 1 clinical trial of a seasonal influenza vaccine based on its ...